National Neuromuscular Research Institute

03/12/2026

Celebrating Histopathology Professionals Day 🔬
Earlier this week on March 10, we recognized Histopathology Professionals Day and took a moment to celebrate the incredible work of our Histotechnician, Britni.

From carefully preparing tissue samples to producing the high-quality slides our pathologists rely on, Britni’s precision, dedication, and expertise help turn tiny sections of tissue into life-saving diagnoses every day.

Histopathology professionals play a vital behind-the-scenes role in patient care, ensuring every specimen is processed with accuracy so providers can deliver the answers patients need.

Thank you, Britni, for your hard work, attention to detail, and commitment to excellence. We’re grateful to have you on our team!

03/06/2026

As a research assistant at NNRI, Mayra has shown incredible dedication and work ethic every day. We’re so proud to see her start nursing school and can’t wait to see the impact she’ll make as a nurse.

Thank you for all that you do, Mayra!

02/28/2026

Today, on Rare Disease Day, we stand with the millions of individuals and families affected by rare neuromuscular diseases.

At NNRI, our mission is rooted in advancing research, expanding access to clinical trials, and supporting patients living with conditions such as CIDP, MG, ALS, FSHD, IBM, and other rare neuromuscular disorders.

While each condition may be rare, together they impact millions worldwide. Through innovation, collaboration, and clinical research, we continue working toward better treatments and improved quality of life.

To our patients, caregivers, researchers, and partners: we see you, we support you, and we remain committed to accelerating progress.

02/20/2026

We are proud to share that Dr. Hussain has been elected President of the Texas Neurological Society (TNS)!

This prestigious honor recognizes Dr. Hussain’s outstanding leadership, dedication to advancing neurological care, and commitment to innovation in research and patient outcomes.

Please join us in congratulating Dr. Hussain on this well-deserved achievement and milestone!

02/05/2026

💙 Shoutout to Emma for her hard work and dedication in reaching this Rainbow Study milestone. NNRI only works because we have incredible employees like you. Thank you, Emma, for all that you do!

Learn more about NNRI's studies:
https://austinneuromuscle.com/clinical-research/

More about the Rainbow study:
https://clinicaltrials.gov/study/NCT06371417?term=RAY902CT&rank=1

01/29/2026

ALS slowly damages motor neurons, leading to loss of voluntary muscle control. With no cure, research is vital. NNRI is conducting research to better understand this condition and exploring potential treatment options through clinical trials.

Learn more about our studies on our website: https://austinneuromuscle.com/clinical-research/

01/22/2026

A platform study for Myasthenia Gravis is now at NNRI.🔬🧬

ADAPT Forward is a Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

More information here:
https://clinicaltrials.gov/study/NCT07294170?term=NCT07294170&rank=1

To learn more or request additional information, please visit our website: https://austinneuromuscle.com/clinical-research/

01/15/2026

The FDA has announced approval of a new treatment option for people living with myasthenia gravis. Progress like this reflects the broader efforts of the clinical research community. We’re grateful for our staff’s continued dedication to ethical, high-quality research.

, /PRNewswire/ -- (NASDAQ:AMGN) today announced that the (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. The approval offe...

01/08/2026

How clinical research is exploring new pathways for communication in ALS🧠🔬

ALS is a progressive neurodegenerative disease that affects motor neurons, often making communication increasingly difficult over time. Research into assistive technologies, including brain computer interfaces like Neuralink, is exploring how communication may be supported in the future through clinical studies.

This KXAN story highlights one individual’s personal experience living with ALS and participating in a Neuralink clinical trial. The patient’s perspective reflects the daily challenges ALS can bring, particularly related to mobility and communication, and the importance of ongoing, ethical research in this space. We are grateful to individuals who choose to share their stories publicly and contribute to clinical research.

01/01/2026

As we welcome in this new year, we’re especially thankful for our dedicated employees and the patients who place their trust in us.
Happy New Year from all of us at NNRI 💙

12/23/2025

We’re proud to see Dr. Yessar Hussain, Director of the National Neuromuscular Research Institute and Austin Neuromuscular Center, featured in this KXAN story on ALS and emerging assistive technology, .

There is still no cure for ALS, but innovation—combined with comprehensive neuromuscular care—can help support quality of life and independence for patients and families.

Technologies like Neuralink are not treatments or cures; however, they raise important questions about how assistive technology may support communication and independence for people living with paralysis.

At NNRI and ANC, our focus remains on evidence-based care, ongoing research, and supporting patients at every stage of neuromuscular disease.




🔗 Learn more about ALS care and research at: https://austinneuromuscle.com/about/

https://www.kxan.com/news/science/neuralink-provides-austin-man-wings-after-als-diagnosis/

Jake Schneider, an ALS patient, was able to reconnect with the world through Neuralink, a brain-computer interface device that allows him to control a cursor on a screen and play video games with h…